<DOC>
	<DOC>NCT01330953</DOC>
	<brief_summary>The purposes of this study are (1) To determine the safety of LY2928057 in healthy people, and any side effects that might be associated with it; (2) To understand how the body of healthy people handles LY2928057; (3) To determine the effect of LY2928057 on blood iron level in people's body; and (4) To evaluate how people's immune system reacts to LY2928057.</brief_summary>
	<brief_title>A First Human Study of a Ferroportin Antibody</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>Must either be a healthy male (and willing to use reliable method of birth control during the study and for 3 months following the last dose of study drug), or a healthy female who cannot become pregnant Must have a body mass index (BMI) between 18.5 and 32.0 kg/mÂ², inclusive and a minimum body weight of 55 kg Blood and urine laboratory test results must be acceptable for the study The veins must be suitable for easy blood collection and study drug administration Must be reliable and willing to be available for the duration of the study and are willing to follow study procedures Must have given written informed consent Blood pressure and pulse rate must be acceptable for the study Blood test shows that subject has anemia due to lack of iron Currently taking part in another clinical study or completed one less than 30 days ago Allergic to biologic agents Have previously taken part in this study Have abnormal electrocardiogram (ECG) findings that suggests an increase in the risks associated with participating in the study Have a history of significant disease that may affect the actions of drugs or may pose a risk when taking the study medication Have a history of drug or alcohol abuse Are infected with human immunodeficiency virus (HIV) Have hepatitis B Are pregnant or breast feeding Intend to use overthecounter or prescription medication within 14 days prior to dosing, other than oestrogen/progesterone as hormone replacement therapy (HRT). Subjects taking these medications should be on chronic, stable doses. Certain medications, for example vitamin supplements, may be permitted at the discretion of the investigator. Have donated more than 450 mL of blood within the last 3 months Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female), or you are unwilling to stop alcohol as required for the study (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits) Are a smoker (smoking more than 10 cigarettes per day) or have used equivalent tobacco products. Subjects will not be allowed to smoke while in the study unit. Have received live vaccine(s) within 1 month of screening, or intend to during the study Have received treatment with biologic agents (such as monoclonal antibodies) within 3 months or 5 halflives (whichever is longer) prior to receiving study drug in this study Have a history of atopy, or significant allergies to humanized monoclonal antibodies, or clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis) Have any active mental health illness The study doctor thinks the subject should not participate for any reason</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Anemia</keyword>
</DOC>